BACKGROUND: Effectiveness of L-asparaginase administration in acute lymphoblastic leukemia treatment is mirrored in the overall outcome of patients. Generally, leukemia patients differ in their sensitivity to L-asparaginase; however, the mechanism underlying their inter-individual differences is still not fully understood. We have previously shown that L-asparaginase rewires the biosynthetic and bioenergetic pathways of leukemia cells to activate both anti-leukemic and pro-survival processes. Herein, we investigated the relationship between the metabolic profile of leukemia cells and their sensitivity to currently used cytostatic drugs. METHODS: Altogether, 19 leukemia cell lines, primary leukemia cells from 26 patients and 2 healthy controls were used. Glycolytic function and mitochondrial respiration were measured using Seahorse Bioanalyzer. Sensitivity to cytostatics was measured using MTS assay and/or absolute count and flow cytometry. Mitochondrial membrane potential was determined as TMRE fluorescence. RESULTS: Using cell lines and primary patient samples we characterized the basal metabolic state of cells derived from different leukemia subtypes and assessed their sensitivity to cytostatic drugs. We found that leukemia cells cluster into distinct groups according to their metabolic profile. Lymphoid leukemia cell lines and patients sensitive to L-asparaginase clustered into the low glycolytic cluster. While lymphoid leukemia cells with lower sensitivity to L-asparaginase together with resistant normal mononuclear blood cells gathered into the high glycolytic cluster. Furthermore, we observed a correlation of specific metabolic parameters with the sensitivity to L-asparaginase. Greater ATP-linked respiration and lower basal mitochondrial membrane potential in cells significantly correlated with higher sensitivity to L-asparaginase. No such correlation was found in the other cytostatic drugs tested by us. CONCLUSIONS: These data support that cell metabolism plays a prominent role in the treatment effect of L-asparaginase. Based on these findings, leukemia patients with lower sensitivity to L-asparaginase with no specific genetic characterization could be identified by their metabolic profile.

CLIP Childhood Leukaemia Investigation Prague Prague Czech Republic

Department of Bioenergetics Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Pediatric Hematology and Oncology National Institute of Children's Diseases and Medical Faculty Comenius University Bratislava Slovakia

University Hospital Motol Prague Czech Republic

Zobrazit více v PubMed

Creutzig U, Zimmermann M, Bourquin J-P, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013;122(1):37–43. doi: 10.1182/blood-2013-02-484097. PubMed DOI

Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174–184. doi: 10.1200/JCO.2013.48.6522. PubMed DOI

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–764. doi: 10.1038/nature05690. PubMed DOI

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, DaSilva A, et al. Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell. 2013;24(6):766-76. PubMed PMC

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018;553(7689):511–514. doi: 10.1038/nature25186. PubMed DOI PMC

Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med. 2013;19(3):368–371. doi: 10.1038/nm.3078. PubMed DOI PMC

Hermanova I, Arruabarrena-Aristorena A, Valis K, Nuskova H, Alberich-Jorda M, Fiser K, et al. Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia. 2016;30(1):209–218. doi: 10.1038/leu.2015.213. PubMed DOI

Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC, et al. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013;122(6):969–980. doi: 10.1182/blood-2013-03-489468. PubMed DOI

Liang J, Shi P, Guo X, Li J, He L, Wang Y, et al. A retrospective comparison of Escherichia�coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett. 2017;15(1):75–82. PubMed PMC

Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, et al. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. JAMA Oncol. 2018; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29450465. [cited 2018 Apr 18]. PubMed PMC

Woerden NLR, Pieters R, Loonen AH, Hubeek I, Van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3):1094–1099. PubMed

Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia. 1998;12(9):1344–1348. doi: 10.1038/sj.leu.2401129. PubMed DOI

Appel IM, Kazemier KM, Boos J, Lanvers C, Huijmans J, Veerman AJP, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665–1679. doi: 10.1038/leu.2008.165. PubMed DOI

Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L, et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood. 1996;88(3):785–794. doi: 10.1182/blood.V88.3.785.785. PubMed DOI

Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, et al. A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med. 2012;18(9):1350–1358. doi: 10.1038/nm.2882. PubMed DOI PMC

Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim S-H, Mostoslavsky R, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. The EMBO J. 2007;26(7):1913–1923. doi: 10.1038/sj.emboj.7601633. PubMed DOI PMC

Hlozková K, Starková J. Assessment of the Metabolic Profile of Primary Leukemia Cells. Journal of Visualized Experiments. 2018;(141). Available from: https://www.jove.com/video/58426/assessment-of-the-metabolic-profile-of-primary-leukemia-cells. [cited 2019 Jun 21]. PubMed

Pejznochová M, Tesarová M, Honzík T, Hansíková H, Magner M, Zeman J. The developmental changes in mitochondrial DNA content per cell in human cord blood leukocytes during gestation. Physiol Res. 2008;57(6):947–955. PubMed

Hermanova I, Zaliova M, Trka J, Starkova J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Exp Hematol. 2012;40(8):657–665. doi: 10.1016/j.exphem.2012.04.005. PubMed DOI

Okada S, Hongo T, Yamada S, Watanabe C, Fujii Y, Ohzeki T, et al. In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol. 2003;123(5):802–809. Available from: http://doi.wiley.com/10.1046/j.1365-2141.2003.04703.x. [cited 2020 Apr 16]. PubMed DOI

Hung YP, Teragawa C, Kosaisawe N, Gillies TE, Pargett M, Minguet M, et al. Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. eLife. 2017;6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29239720. [cited 2019 Oct 8]. PubMed PMC

Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18(20):5546–5553. doi: 10.1158/1078-0432.CCR-12-0977. PubMed DOI PMC

Shin Y-K, Yoo BC, Chang HJ, Jeon E, Hong S-H, Jung M-S, et al. Down-regulation of Mitochondrial F 1 F 0 -ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance. Cancer Res. 2005;65(8):3162–3170. doi: 10.1158/0008-5472.CAN-04-3300. PubMed DOI

Perry SW, Norman JP, Barbieri J, Brown EB, Harris A. Gradient : a Practical Usage Guide. Biotechniques. 2011;50(2):98–115. doi: 10.2144/000113610. PubMed DOI PMC

Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:S1–S9. doi: 10.1097/CCO.0b013e32835d7d85. PubMed DOI

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5(11):2613–2623. doi: 10.1158/1535-7163.MCT-06-0447. PubMed DOI

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 2018;554(7692):378–381. doi: 10.1038/nature25465. PubMed DOI PMC

Panosyan EH, Wang Y, Xia P, Lee W-NP, Pak Y, Laks DR, et al. Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors. Mol Cancer Res. 2014;12(5):694–702. doi: 10.1158/1541-7786.MCR-13-0576. PubMed DOI PMC

Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, et al. L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012;16(10):2369–2378. doi: 10.1111/j.1582-4934.2012.01547.x. PubMed DOI PMC

PTEN/PI3K/Akt pathway alters sensitivity of T-cell acute lymphoblastic leukemia to L-asparaginase